Abstract

Aseptic loosening is a primary mode of failure in cemented total joint surgery. Fatigue and eventual fracture of the cement mantle may be an important mechanism by which aseptic loosening occurs. Microcracking due to repetitive loading of the cement mantle has been implicated as a primary mechanism of failure in cemented femoral hip arthroplasties (1). This was the motivation behind the development of a new commercial bone cement formulation, known as Osteobond, designed to have an extended fatigue lifetime. Although the ultimate pre-clinical demonstration of enhanced in vivo performance remains the animal model, these studies are expensive and often inconclusive (2). Therefore, standard laboratory fatigue testing was employed (3). The fatigue performance of Osteobond was compared with that of Howmedica’s Simplex P using both open bowl mixing and vacuum mixing to prepare the samples.

This content is only available via PDF.
You do not currently have access to this content.